Measurement Sensitivity Analysis for Pharma Media
How to stress-test pharma media measurement conclusions by changing one assumption at a time and noting when the recommendation reverses.
The short answer
Every pharma media measurement result rests on assumptions: the attribution window, the comparison group, how missing data was handled, the outcome definition. A sensitivity analysis changes those assumptions one at a time to see whether the conclusion holds. If a reasonable change reverses the recommendation, the result is fragile and should be treated with caution.
This is one of the most useful and least used steps in pharma measurement.
Why it matters
Measurement results are often presented as a single number: "18% lift." That number reflects many choices made by the analyst or vendor. Different reasonable choices could produce 8% or 25%. Decision makers rarely see this range. A sensitivity analysis shows it.
What to vary
| Assumption | Typical alternatives to test |
|---|---|
| Attribution window | Shorter and longer than the base case |
| Outcome definition | New-to-brand vs. total prescriptions |
| Comparison group | Different matching variables or methods |
| Exposure threshold | Any exposure vs. a minimum frequency |
| Missing data | Exclude vs. impute unmatched records |
| Time period | Remove unusual weeks, such as holidays |
You do not need to test everything. Focus on assumptions that are most uncertain and most likely to affect the result.
Build the sensitivity table
Show the base result and each variation side by side, with the recommendation each implies.
| Scenario | Estimated lift | Interval | Recommendation |
|---|---|---|---|
| Base case (60-day window) | 12% | 4% to 20% | Scale |
| 30-day window | 9% | 1% to 17% | Scale |
| 90-day window | 14% | 5% to 23% | Scale |
| New-to-brand only | 6% | -3% to 15% | Hold |
| Stricter matching | 8% | -1% to 17% | Hold |
These figures are illustrative. In this example, the result holds across windows but weakens under stricter matching and a narrower outcome. The brand should be cautious about claiming a large new-patient effect.
Read the pattern
- Result holds across all variations: you can act with more confidence.
- Result reverses under one plausible change: investigate that assumption before acting.
- Result swings widely: the evidence is weak; consider a better-designed follow-up test.
Ask vendors for sensitivity results
Measurement vendors can often run alternative windows or outcome definitions. Ask for them. If a vendor presents only one result without alternatives, ask what would change it. See how to choose an attribution window and why Rx match rates drop.
Keep it honest
Sensitivity analysis can be misused to hunt for the most favorable result. Decide which variations you will test before seeing results, and report all of them. The ASA's statement on p-values cautions against selective reporting.
Practical takeaway
For every major measurement result, ask for a sensitivity table with at least three variations of the most uncertain assumptions. Include it in the investment case alongside the base result.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.